Beamion LUNG-1 study results for zongertinib in treatment-naïve patients with HER2-mutant advanced NSCLC published in The New England Journal of Medicine

Notified -

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer

Notified -

Io Therapeutics, Inc. announces publication of studies on the company’s RXR agonist compound IRX4204 for breast cancer prevention

Notified -

Io Therapeutics presents today at the American Society for Hematology Annual Meeting, preclinical studies demonstrating combination treatment with BCMA CAR-T cells plus the company's RXR agonist compound IRX4204 has synergistic efficacy against human mul

Notified -

Curium Establishes Legal Entity in China

Notified -

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

Notified -

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

Notified -

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Notified -

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Notified -

Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer

Notified -

Io Therapeutics, Inc., announces presentation of data on its RAR gamma agonist compound IRX5010 demonstrating inhibition of tumor infiltrating myeloid derived suppressor cells, promotion of tumor infiltrating T-cells, and effective tumor growth inhibition